Cullinan Therapeutics, Inc. (CGEM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 8, 2025, discloses the presentation of updated clinical data for Cullinan Therapeutics, Inc. at the 67th American Society of Hematology (ASH) Annual Meeting. The Company is a biopharmaceutical firm developing CLN-049 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and regulatory updates rather than financial performance.
Material Changes and Clinical Results
The primary material event is the release of Phase 1 efficacy and safety data for CLN-049 as of an August 2025 data cutoff. Key findings include:
- Study Population: 45 patients enrolled (39 AML, 3 MDS/AML, 3 MDS) across eight cohorts with target doses ranging from 1.5 to 12 µg/kg.
- Efficacy in AML:
- At the 12 µg/kg dose (n=16), the Complete Response/Complete Remission with partial hematologic recovery (CR/CRh) rate was 31% (5/16).
- At doses ≥6 µg/kg (n=32), the CR/CRh rate was 25% (8/32) and the composite complete response (CRc) rate was 28% (9/32).
- TP53-Mutated AML: Among 8 patients treated at 12 µg/kg, 50% (4/8) achieved a CR/CRh response.
- Durability: At efficacious doses (≥6 µg/kg), 63% (5/8) of patients achieving CR/CRh had a response duration >16 weeks. One MRD-negative patient had an ongoing response >36 weeks.
- Safety Profile: The most common treatment-emergent adverse events were cytokine release syndrome (CRS) (35.6%) and infusion-related reactions (33.3%). Nearly all CRS events were Grade 1 or 2; no Grade 3 CRS was observed with two step-up doses.
Guidance, Outlook, and Risks
Outlook: CLN-049 development will proceed under U.S. FDA Fast Track designation. Dose escalation continues in the ongoing Phase 1 study, with expansion cohorts planned for early 2026.
Risks and Contingencies: The filing notes that the information furnished pursuant to Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. Clinical development carries inherent risks regarding efficacy and safety in broader populations.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical tables and patient demographics.
- Confirm the timeline for the planned expansion cohorts in early 2026.
- Monitor subsequent filings for updates on the FDA Fast Track designation status.
- Review the Company's most recent 10-K or 10-Q for current cash runway and burn rate, as this 8-K contains no financial data.